Invention Grant
US08685999B2 Beta carboline sulphonylurea derivatives as EP4 receptor antagonists
有权
β咔啉磺酰脲衍生物作为EP4受体拮抗剂
- Patent Title: Beta carboline sulphonylurea derivatives as EP4 receptor antagonists
- Patent Title (中): β咔啉磺酰脲衍生物作为EP4受体拮抗剂
-
Application No.: US13120786Application Date: 2009-09-22
-
Publication No.: US08685999B2Publication Date: 2014-04-01
- Inventor: Carl Berthelette , Michael Boyd , Jason Burch , Claude Dufresne , Julie Farand , Yongxin Han , Claudio F. Sturino
- Applicant: Carl Berthelette , Michael Boyd , Jason Burch , Claude Dufresne , Julie Farand , Yongxin Han , Claudio F. Sturino
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Maria V. Marucci; Valerie J. Camara
- International Application: PCT/CA2009/001330 WO 20090922
- International Announcement: WO2010/034110 WO 20100401
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/437
Abstract:
The invention is directed to β-carboline sulphonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, inflammation, osteoarthritis, and rheumatoid arthritis. Pharmaceutical compositions and methods of use are also included.
Public/Granted literature
- US20110275660A1 BETA CARBOLINE SULPHONYLUREA DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS Public/Granted day:2011-11-10
Information query
